Premium
Performance of ANTI‐HCV testing in dried blood spots and saliva according to HIV status
Author(s) -
Flores Geane Lopes,
Cruz Helena Medina,
Marques Vanessa Alves,
VillelaNogueira Cristiane Alves,
Potsch Denise Vigo,
May Silvia Beatriz,
BrandãoMello Carlos Eduardo,
Pires Marcia Maria Amendola,
Pilotto Jose Henrique,
PolloFlores Priscila,
Esberard Eliane Bordalo Cathalá,
Ivantes Claudia,
LewisXimenez Lia Laura,
Lampe Elisabeth,
Villar Livia Melo
Publication year - 2017
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.24777
Subject(s) - saliva , dried blood spot , medicine , hepatitis c virus , dried blood , viral load , immunoassay , virology , immunology , human immunodeficiency virus (hiv) , virus , antibody , biology , chemistry , chromatography , genetics
The use of saliva and dried blood spots (DBS) could increase access to HCV diagnosis for high‐risk populations, such as HIV‐infected individuals, but the performance of these assays has not been well established in this group. This study aims to evaluate HIV status, particularly TCD4 + cell count and viral load, in the performance of anti‐HCV testing using DBS and saliva. A total of 961 individuals classified as HCV+, HIV+, or HIV/HCV+, as well as negative controls, donated serum, DBS, and saliva samples for anti‐HCV testing using a commercial enzyme immunoassay. Sample volume was modified for DBS and saliva, and an ROC curve was used for cut‐off determination in saliva. Anti‐HCV sensitivities were greater than 93% using DBS and saliva in the HCV+ group, while they were 83.3% and 95.6% for HCV/HIV+ individuals for DBS and saliva assays, respectively. Specificity varied from 91.7% to 100% using saliva and DBS in HIV monoinfected and control subjects. When only anti‐HCV/HCV RNA+ serum samples, that is, true positives, were considered, the sensitivities were 98.3% and 100% for DBS and saliva, respectively, in the HCV+ group and 91.6% and 94.8% for DBS and saliva, respectively, in the HIV/HCV+ group. High absorbance values were observed among those presenting with HCV RNA in serum and low HIV viral load (less than 50 copies/mL). In conclusion, DBS and saliva samples could be used for anti‐HCV detection, particularly to identify active HCV cases, but low sensitivity was observed for anti‐HCV testing using DBS in the HIV/HCV+ group.